NCT04175158Unknown1 期
A Randomized, Double-blind, Parallel-controlled Comparative Study to Evaluate the PK Pharmacokinetic Similarity After Single Administration of GB222 and Bevacizumab in Healthy Volunteers.
适应症
干预措施
试验速览
- 阶段
- 1 期
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- AUC 0- t
研究概览
简要总结
The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and similarities and safety of other pharmacokinetic (PK) parameters (Cmax, AUC0-∞ etc.) and immunogenicity of GB222 and bevacizumab after single administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subjects who voluntarily participated in the clinical study and sign the informed consent form;
- •Healthy male adult volunteers aged 18 to 45 years;
- •The subjects have qualified physical examination within 28 30 days before the study, the body mass index (BMI) is within the range of 19.0~24.0, 50kg for males³ and 45kg for females³, the body weight of males and females is not more than 75kg (inclusive);
- •The subjects agree and adopt reliable contraceptive methods to ensure that they have no pregnancy plain from the beginning of the study to 6 months after the end of this study;
- •Based on physical examination, medical history, vital signs, electrocardiogram, etc., the researchers determined that the body condition of participant was good;
- •The subjects can well communicate with the investigators and complete the study as required by the study.
- •Exclusions：
- •Allergic constitution; known allergic to the components of the investigational product or allergy history to any drug or food or pollen; subjects who have abnormal serum immunoglobulin E (IgE);
- •Any current signs and symptoms or abnormalities in laboratory tests may indicate acute or subacute infection (fever, cough, urination, pain, abdominal pain, diarrhea, skin infection, wound, etc.)
- •History of drug addiction or drug abuse; subjects with positive urine drug screening;
- •Clear medical history of central nervous system, cardiovascular, renal, hepatic, gastrointestinal, respiratory, metabolic system or other significant diseases; medical history of hypertension or screening systolic blood pressure³ of 140mmHg and/or diastolic blood pressure³ of 90mmHg,which are clinically significant at the discretion of the investigators;
- •People with malignant tumors;
- •Participated in other clinical studies within 3 months before enrollment, or subjects who received drugs which are known to injure the major organs within 3 months before enrollment;
- •Blood donation within 3 months before enrollment;
- •Surgery operation within 3 months before enrollment;
- •Use of prescription drugs or non-prescription drugs within 14 days before enrollment;
- •ALT or AST>1.5 ULN, Cr>ULN;
- •Hematology test: WBC<3.0×10 9 /L or > 9.5×10 9 /L; ANC < 1.5×10 9 /L; PLT<100×10 9/L; HGB<104 g/L,conform to any of these items;
- •Any of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) and anti-treponema pallidum antibody (TP-Ab);
- •Subjects who have positive anti-drug antibody (ADA);
- •Positive tumor marker (CEA、AFP、PSA、CA-125);
- •Abnormal coagulation function, which is judged by the researcher to be clinically significant;
- •Patients with a previous history of digestive tract ulcer, cerebrovascular accident, vascular lesions, etc., currently have open wounds of skin and mucosa. The researchers considered that other volunteers with risk of bleeding or coagulation should not be included in the study
- •Patients with a history of mental illness.
排除标准
- 未提供
研究组 & 干预措施
Bevacizumab
Active Comparator
1mg/kg
干预措施: Bevacizumab (Biological)
GB222
Experimental
1mg/kg
干预措施: GB222 (Biological)
结局指标
主要结局
AUC 0- t
时间窗: Up to 84 days
AUC 0- t
次要结局
- Cmax(Up to 84 days)
- AUC0-∞(Up to 84 days)
- ADA(Up to 84 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaMelanomaNCT06153238Sandoz322
已完成
1 期
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFSCrohn DiseaseAnkylosing SpondylitisPediatric Crohns DiseaseNon-infectious UveitisPolyarticular Juvenile Idiopathic ArthritisHidradenitis SuppurativaPediatric Plaque PsoriasisPlaque PsoriasisRheumatoid ArthritisUlcerative ColitisPsoriatic ArthritisNCT04018599Fresenius Kabi SwissBioSim GmbH216
已完成
1 期
A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy VolunteersHealthy VolunteerNCT05216887Biogen123
已完成
1 期
Evaluate Safety, Efficacy and PharmacokineticsMetastatic Breast CancerNCT01084863Celltrion143
已完成
1 期
A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy SubjectsHealthyNCT05974969Biocad146